

POST-STERNOTOMY MEDIASTITIS: A MEDICOECONOMIC STUDY COMPARING TWO PREVENTIVE STRATEGIES IN CARDIAC SURGERY

Anne-Laure ANTOINE¹, Maïra GAILLARD², Julien GUIHAIRE², Matthieu POUTEAUX³, Guillaume HEBERT¹, Aziza GHAZOUANI¹

¹ Hospital pharmacy department, ² Adult cardiac surgery department, ³ Management control department,

Marie Lannelongue hospital, 133 avenue de la Résistance, 92350 LE PLESSIS ROBINSON, France - anne-laure.antoine@intradef.gouv.fr

BACKGROUND AND IMPORTANCE

Open heart surgery

Risk of postoperative mediastinitis = serious sternal wound infection
→ Causing excess mortality and prolonged hospitalizations

The risk factors (RF) found in the literature are :

- Coronary artery bypass with bilateral internal mammary grafting (BIMA)
- Insulin-dependant diabetes / obesity / chronic obstructive pulmonary disease (COPD) / history of mediastinal radiotherapy / active smoking

Incidence of postoperative mediastinitis

Marie Lannelongue hospital (HML) : 4,2% (2020)	>	Literature up to 3%/year
--	---	--------------------------

Two preventive strategies are considered :

- Insertion during sternal closure of the **COLLATAMPG®** (Serb), bioabsorbable bovine collagen implant impregnated with gentamicin
- Immediate postoperative application of negative pressure therapy to the sternal wound with the **PICO®7** system (Smith & Nephew)



COLLATAMPG®



PICO®7

AIM AND OBJECTIVES

- ① Compare the **cost-effectiveness** of these two preventive strategies
- ② Evaluate the **impact** on **length of stay** and **antibiotic (ATB) consumption**

MATERIALS AND METHODS

Cost-effectiveness analysis

- Monocentric – 3 arms
 - **1 retrospective control arm** – standard sternal dressing = **MEPORE®** (Molnlycke) → 01/07/2019 – 30/09/2019 → Identification of HML patients on the national EPICARD database
 - **2 prospective intervention arms** – **COLLATAMPG®** and **PICO®7** → 23/11/2020 – 19/02/2021
- Comparison of **COLLATAMPG®** and **PICO®7** arm versus control arm

COST STUDY

- ✓ Calculation of **postoperative hospital costs** for each strategy
 - **Consumed resources evaluated by microcosting** → Medical device (MD) / ATB → *management software (Qualiac®)*
 - **Hospital stays + reoperations evaluated by reference cost** → Cost of a day in care unit and intensive care unit at HML → Operating room hourly rate at HML

Calculation of the **incremental cost effectiveness ratio (ICER)**

PATIENT INCLUSION AND EXCLUSION CRITERIA

- ✓ **Inclusion** : open heart surgery + at least one postoperative mediastinitis RF (coronary artery bypass with BIMA, BMI ≥ 30kg/m², treated diabetes, active smoker, treated COPD, history of mediastinal radiotherapy)
- ✓ **Exclusion** : deaths from non-infectious causes during the study period

EFFECTIVENESS STUDY

- ✓ **Primary endpoint** = incidence of mediastinitis at 1 month after surgery (**M1**)
 - Mediastinitis = surgical revision for deep infection of the surgical site with positive bacteriological samples (bone, mediastinal fluid)
 - Inclusion of superficial infections requiring surgical revision and prolonged hospitalization for antibiotic therapy
- ✓ **Secondary endpoints** → *Medical record (Hospital Manager®)*
 - Length of stay (conventional hospitalization / intensive care)
 - ATB consumption

RESULTS

POPULATION

	Control	COLLATAMPG®	PICO®7
Number of patients	48	25	9
Mean age (years)	64 [31;81]	65 [24;84]	60 [47;73]
Male-to-female ratio	7	5,3	3,5
Average number of RF	1,7	1,8	2,4*

* Statistically significant (p < 0,05 – Chi² test)

PRIMARY ENDPOINT


DIAGNOSIS OF MEDIASTITIS AT M1

	Control	COLLATAMPG®	PICO®7
Number of mediastinitis	4	1	1
Number of reversed suspicions	0	2	0
Incidence of mediastinitis	8,3%	4,0%	11,1%

⇒ **PICO®7 arm** * Statistically significant (p < 0,05 – Fisher test)

- Average application time = 4,7 days
- 2 cases of air leak in patients with high BMI (>34kg/m²) making the system ineffective

SECONDARY ENDPOINTS



DISTRIBUTION OF RF



NATURE OF INTERVENTIONS (n=82)



POSTOPERATIVE HOSPITAL COSTS

CONTROL ARM			COLLATAMPG® ARM			PICO®7 ARM		
Hospital stay 12 238€ 95,2%			Hospital stay 9 845€ 94,2%			Hospital stay 12 105€ 98,7%		
ATB 124€ 1,0%	MD 0,4€ <0,1%	Surgical revision 497€ 3,8%	ATB 8€ 0,1%	MD 125€ 1,2%	Surgical revision 472€ 4,5%	ATB 38€ 0,3%	MD 120€ 1,0%	Surgical revision 864€ 6,6%
12 860€/patient			10 451€/patient			13 127€/patient		

ICER = ΔCost/ΔIncidence

- ICER (COLLATAMPG® vs control) = 55 583€/mediastinitis avoided
- ICER (PICO®7 vs control) = 9 616€/mediastinitis avoided

CONCLUSION AND RELEVANCE

Comparison of the two preventive strategies

- The difference in the incidence of mediastinitis is not significant (p > 0,05)
- The ICER is positive for COLLATAMPG® and PICO®7 → **prevention reduces costs**
- **Both strategies are more cost effective than standard sternal dressing**
- **The ICER is in favor of COLLATAMPG®**
- **PICO®7 arm** → the average number of RF is statistically higher (p < 0,05) and the observed leaks can be resolved

Problem of study power → Short study duration and low incidence of mediastinitis

- ✓ **By supporting surgical teams in the evaluation of preventive strategies the hospital pharmacist contributes to optimize treatments at the best cost**

Impact on length of stay

- Not significant for COLLATAMPG® and PICO®7 (p > 0,05)

Impact on ATB consumption

- Not significant for COLLATAMPG® and PICO®7 (p > 0,05)

Perspectives

- Leakage problem of PICO®7 : addition of a **RENASYS®** (Smith & Nephew) sealing patch when there is a risk of leakage, under test → medico-economic impact to be re-evaluated with this parameter
- Continue the study with a larger number of patients by extending the inclusion period or expanding to other centers